Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced an upcoming late-breaking poster presentation at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting. The presentation will focus on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia treatment.
The presentation, scheduled for May 28, 2025, from 11:15 a.m. to 1 p.m. MT at the Fairmont Scottsdale Princess in Arizona, will be delivered by Dr. Laxminarayan Bhat, the company's Founder, President, and CEO. The poster will detail brilaroxazine's effects on efficacy, safety, adherence, and biomarkers in patients with stable schizophrenia during the Phase 3 RECOVER trial extension.
Reviva, a late-stage pharmaceutical company, is developing therapies targeting unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha annunciato una presentazione poster di ultima ora al congresso annuale della American Society of Clinical Psychopharmacology (ASCP) 2025. La presentazione si concentrerà sullo studio di estensione open label a 12 mesi RECOVER per brilaroxazine nel trattamento della schizofrenia.
L'intervento, previsto per il 28 maggio 2025, dalle 11:15 alle 13:00 MT presso il Fairmont Scottsdale Princess in Arizona, sarà tenuto dal dott. Laxminarayan Bhat, fondatore, presidente e CEO dell’azienda. Il poster illustrerà gli effetti di brilaroxazine su efficacia, sicurezza, aderenza e biomarcatori in pazienti con schizofrenia stabile durante l’estensione della fase 3 dello studio RECOVER.
Reviva, azienda farmaceutica in fase avanzata, sviluppa terapie mirate a bisogni medici non soddisfatti nelle malattie del sistema nervoso centrale (SNC), infiammatorie e cardiometaboliche.
Reviva Pharmaceuticals (NASDAQ: RVPH) ha anunciado una presentación de póster de última hora en la reunión anual de la American Society of Clinical Psychopharmacology (ASCP) 2025. La presentación se centrará en el ensayo de extensión abierta a 12 meses RECOVER para brilaroxazine en el tratamiento de la esquizofrenia.
La presentación, programada para el 28 de mayo de 2025, de 11:15 a.m. a 1 p.m. MT en el Fairmont Scottsdale Princess en Arizona, será realizada por el Dr. Laxminarayan Bhat, fundador, presidente y CEO de la compañía. El póster detallará los efectos de brilaroxazine sobre la eficacia, seguridad, adherencia y biomarcadores en pacientes con esquizofrenia estable durante la extensión del ensayo de fase 3 RECOVER.
Reviva, una compañía farmacéutica en etapa avanzada, está desarrollando terapias que abordan necesidades médicas no cubiertas en enfermedades del sistema nervioso central (SNC), inflamatorias y cardiometabólicas.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 2025년 미국 임상 정신약리학회(ASCP) 연례회의에서 긴급 포스터 발표를 예정하고 있다고 발표했습니다. 이번 발표는 조현병 치료를 위한 brilaroxazine의 RECOVER 12개월 오픈라벨 연장 시험에 초점을 맞출 예정입니다.
발표는 2025년 5월 28일 오전 11시 15분부터 오후 1시까지 애리조나 페어몬트 스코츠데일 프린세스에서 진행되며, 회사의 창립자이자 사장 겸 CEO인 Dr. Laxminarayan Bhat가 발표를 맡습니다. 포스터는 3상 RECOVER 시험 연장 기간 동안 안정된 조현병 환자에서 brilaroxazine의 효능, 안전성, 복약 순응도 및 바이오마커에 대한 영향을 상세히 설명할 예정입니다.
후기 단계 제약사인 Reviva는 중추신경계(CNS), 염증성 질환 및 심장대사 질환 분야에서 미충족 의료 수요를 겨냥한 치료제를 개발하고 있습니다.
Reviva Pharmaceuticals (NASDAQ : RVPH) a annoncé une présentation poster de dernière minute lors de la réunion annuelle de la American Society of Clinical Psychopharmacology (ASCP) 2025. Cette présentation portera sur l’essai d’extension en ouvert de 12 mois RECOVER pour brilaroxazine dans le traitement de la schizophrénie.
La présentation, prévue le 28 mai 2025 de 11h15 à 13h00 MT au Fairmont Scottsdale Princess en Arizona, sera assurée par le Dr Laxminarayan Bhat, fondateur, président et PDG de l’entreprise. Le poster détaillera les effets de brilaroxazine sur l’efficacité, la sécurité, l’observance et les biomarqueurs chez des patients atteints de schizophrénie stable lors de l’extension de l’essai de phase 3 RECOVER.
Reviva, une entreprise pharmaceutique en phase avancée, développe des thérapies ciblant des besoins médicaux non satisfaits dans les maladies du système nerveux central (SNC), inflammatoires et cardiométaboliques.
Reviva Pharmaceuticals (NASDAQ: RVPH) hat eine kurzfristige Posterpräsentation auf der Jahresversammlung der American Society of Clinical Psychopharmacology (ASCP) 2025 angekündigt. Die Präsentation wird sich auf die 12-monatige offene Verlängerungsstudie RECOVER für brilaroxazine bei der Behandlung von Schizophrenie konzentrieren.
Die Präsentation findet am 28. Mai 2025 von 11:15 bis 13:00 Uhr MT im Fairmont Scottsdale Princess in Arizona statt und wird von Dr. Laxminarayan Bhat, Gründer, Präsident und CEO des Unternehmens, gehalten. Das Poster wird die Wirkungen von brilaroxazine auf Wirksamkeit, Sicherheit, Therapietreue und Biomarker bei Patienten mit stabiler Schizophrenie während der Phase-3-RECOVER-Verlängerung detailliert darstellen.
Reviva, ein Unternehmen in der späten Entwicklungsphase, entwickelt Therapien für ungedeckte medizinische Bedürfnisse im Bereich des zentralen Nervensystems (ZNS), entzündlicher Erkrankungen und kardiometabolischer Krankheiten.
- None.
- None.
CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ.
Details for the poster presentation can be found below:
Title: Brilaroxazine’s Effects on Efficacy, Safety, Adherence, and Biomarkers in the Phase 3 Recover 12-Month Open-Label Trial Extension in Patients with Stable Schizophrenia
Date: Wednesday, May 28, 2025
Time: 11:15 a.m. – 1 p.m. MT
Presenter: Laxminarayan Bhat, Reviva Pharmaceuticals
Location: Fairmont Scottsdale Princess, Scottsdale, AZ
Abstract and additional details are available on the 2025 ASCP annual meeting website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
What will be presented about brilaroxazine at the 2025 ASCP meeting by RVPH?
When and where is RVPH presenting their brilaroxazine trial results?
What therapeutic areas does RVPH focus on in their drug development?
What phase is brilaroxazine in for schizophrenia treatment by RVPH?
